# FYB1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The FYB1 gene encodes ADAP/SLAP-130, a crucial intracellular adapter protein that orchestrates signal transduction downstream of T-cell receptors (TCR), integrins, and NK cell activating receptors, playing a vital role in adaptive immunity, hemostasis, and oncogenesis.
- FYB1 functions as a molecular scaffold, nucleating multi-protein signaling complexes that couple receptor engagement to cytoskeletal reorganization, integrin activation (inside-out signaling), and transcriptional programs, notably through interactions with SLP-76, FYN, SKAP1, and VAV1.
- Germline loss-of-function mutations in FYB1 lead to a rare form of combined immunodeficiency (CID) characterized by recurrent infections and autoimmunity, with diagnostic confirmation requiring flow cytometric assessment of FYB1 protein expression and functional assays like LFA-1 adhesion.
- FYB1 is a target for viral immune evasion strategies, with viral proteins like HIV-1 Nef and Vaccinia virus A36R hijacking FYB1 to disrupt T-cell signaling and promote viral spread, presenting potential therapeutic avenues for immunomodulation.
- Therapeutic strategies targeting FYB1 include small-molecule inhibitors of the FYB1 SH3 domain-SLP-76 interaction, inhibitors of FYB1 phosphorylation (e.g., Dasatinib), and proteolysis-targeting chimeras (PROTACs) for targeted degradation, alongside gene therapy approaches for FYB1 deficiency.

---

## Executive Summary & Key Metadata

The **FYB1** gene (FYN binding protein 1, also known as **ADAP** – Adhesion and Degranulation Promoting Adapter Protein, or **SLAP-130** – SLAP-associated protein of 130 kDa) encodes a critical intracellular adapter protein that orchestrates signal transduction cascades downstream of T-cell antigen receptors (TCR), integrins, and natural killer (NK) cell activating receptors. FYB1 is a scaffolding molecule devoid of intrinsic enzymatic activity; instead, it nucleates multi-protein signaling complexes that couple receptor engagement to cytoskeletal reorganization, integrin activation (inside-out signaling), and transcriptional programs. Its functional relevance spans adaptive immunity, hemostasis, and oncogenic transformation.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | FYB1 |
| **UniProt Accession** | O15117 |
| **Representative PDB ID** | 3O1D (SH3 domain of FYN in complex with FYB1 peptide); 2K0A (NMR structure of FYB1 SH3 domain) |
| **Chromosomal Locus** | 5p13.1 (GRCh38: chr5:39,190,000–39,240,000) |
| **Primary Molecular Function** | Adapter/scaffold protein in TCR, integrin, and NK cell signaling; regulates actin polymerization, cell adhesion, degranulation, and NF-κB/AP-1 transcriptional activation |
| **Disease & Pathology Associations** | Immunodeficiency (combined immunodeficiency with autoimmunity), susceptibility to bacterial/viral infections, altered cancer progression (melanoma, leukemia), and potential roles in autoimmune diseases (rheumatoid arthritis, lupus) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *FYB1* gene is located on the short arm of human chromosome 5 at cytogenetic band **5p13.1**. The genomic span is approximately 50 kilobases (kb), oriented on the minus strand of the reference genome (GRCh38). The gene comprises **21 exons** and **20 introns**, with the translation initiation codon located in exon 2 and the stop codon in exon 21. The core promoter region lacks a canonical TATA box but contains a high GC content (approximately 65%), characteristic of housekeeping and signal-responsive genes. Multiple **SP1** and **Ets-family** transcription factor binding sites are clustered within the proximal promoter (−300 to −50 bp relative to the transcription start site, TSS), which are essential for basal transcription in hematopoietic cells.

### 1.2 Promoter Architecture and Enhancer Elements

Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE and the Roadmap Epigenomics Consortium reveal that the *FYB1* promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer/promoter) in CD4+ and CD8+ T cells, NK cells, and megakaryocytes. A distal enhancer element located approximately 15 kb upstream of the TSS (chr5:39,175,000–39,180,000) contains binding motifs for **GATA-3** and **RUNX1**, both of which are master regulators of T-cell and myeloid differentiation. This enhancer physically loops to the promoter in T cells, as confirmed by Hi-C and 3C-seq experiments, and is required for optimal *FYB1* expression following TCR stimulation.

### 1.3 Transcription Factor Binding and Regulation

The proximal promoter contains a canonical **NF-κB** binding site (GGGRNNYYCC) at position −120 to −110, which is functionally responsive to TCR engagement. Upon TCR crosslinking, the IKK complex phosphorylates IκBα, leading to its degradation and nuclear translocation of p65/p50 heterodimers. These dimers bind the *FYB1* promoter NF-κB site, driving a 3- to 5-fold increase in *FYB1* mRNA within 2–4 hours post-stimulation. Additionally, an **AP-1** (Activator Protein-1) binding site (TGACTCA) at −80 to −74 is bound by c-Fos/c-Jun heterodimers downstream of the Ras-MAPK pathway, providing a secondary amplification loop.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of *FYB1* generates multiple transcript variants. The canonical transcript (NM_001385362.2) encodes the full-length 783-amino acid protein (UniProt O15117-1). A major splice variant lacking exon 11 (NM_001243093.2) produces a protein isoform (O15117-2) that is 87 amino acids shorter and is predominantly expressed in resting T cells. This isoform lacks a portion of the proline-rich region, which is critical for binding to the SH3 domain of FYN kinase. Consequently, the exon 11-skipped isoform exhibits reduced ability to couple TCR signals to integrin activation.

A third isoform (O15117-3), generated by alternative use of a 5' splice site in exon 14, introduces a premature stop codon, producing a C-terminally truncated protein of 612 amino acids. This isoform is expressed at low levels in NK cells and acts as a dominant-negative regulator, sequestering SLP-76 (SH2 domain-containing leukocyte protein of 76 kDa) without recruiting downstream effectors such as VASP (Vasodilator-stimulated phosphoprotein).

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The FYB1 protein is a 783-amino acid polypeptide with a predicted molecular weight of ~130 kDa (hence the alias SLAP-130). It is an intrinsically disordered protein in large part, but contains several well-defined folded domains and short linear motifs (SLiMs) that mediate protein-protein interactions. The domain architecture from N-terminus to C-terminus is as follows:

| **Domain/Motif** | **Residues** | **Function** |
|---|---|---|
| **N-terminal Coiled-Coil (CC1)** | 1–110 | Homodimerization; interaction with the FERM domain of talin |
| **Proline-Rich Region 1 (PR1)** | 120–210 | Binding to SH3 domains of FYN, SRC, and PLC-γ1 |
| **Nuclear Localization Signal (NLS)** | 215–230 | Mediates nuclear import in activated T cells |
| **SH3 Domain** | 240–300 | Binds proline-rich motifs in SLP-76 and SKAP1 |
| **Proline-Rich Region 2 (PR2)** | 310–400 | Binding to the SH3 domain of FYN and the C-terminal SH3 of PLC-γ1 |
| **Coiled-Coil 2 (CC2)** | 410–480 | Interaction with SKAP1 (Src kinase-associated phosphoprotein 1) |
| **Serine/Threonine-Rich Region** | 490–600 | Phosphorylation sites for PKCθ, ERK, and CK2 |
| **C-terminal Proline-Rich Region (PR3)** | 610–700 | Binding to the SH3 domain of FYN and the WW domain of NEDD4 |
| **C-terminal Coiled-Coil (CC3)** | 701–783 | Interaction with the actin-binding protein VASP and Ena/VASP family |

### 2.2 Structural Biology of the SH3 Domain

The SH3 domain of FYB1 (residues 240–300) has been solved by NMR spectroscopy (PDB: 2K0A). It adopts the canonical SH3 fold comprising five β-strands (β1–β5) arranged in two antiparallel β-sheets, connected by a 3₁₀ helix and a short α-helix. The ligand-binding surface is a hydrophobic groove formed by conserved aromatic residues (Trp252, Tyr259, Phe276, and Pro288). This groove accommodates the canonical PxxP motif of SLP-76 (residues 224–229: PPPVPP). The binding affinity (Kd) is approximately 2.5 μM, as measured by isothermal titration calorimetry (ITC). A second, non-canonical binding site on the SH3 domain, involving the RT-loop (residues 260–270), mediates interaction with the proline-rich region of FYN kinase, enabling a ternary complex of FYB1–SLP-76–FYN.

### 2.3 Coiled-Coil Domains and Dimerization

The N-terminal coiled-coil (CC1) and the central coiled-coil (CC2) are predicted by COILS and PCOILS algorithms to form parallel homodimers. Analytical ultracentrifugation and size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) confirm that full-length FYB1 forms stable homodimers in solution (apparent molecular weight ~260 kDa). The CC1 domain (residues 1–110) contains a heptad repeat (abcdefg)ₙ with hydrophobic residues at positions a and d, stabilizing the dimer interface. Mutagenesis of Leu45 and Leu52 to alanine disrupts dimerization and abrogates FYB1 function in T-cell adhesion assays, demonstrating that dimerization is functionally essential.

### 2.4 Intrinsically Disordered Regions (IDRs)

Approximately 45% of the FYB1 sequence is predicted to be intrinsically disordered by IUPred2A and PONDR VSL2. These IDRs are enriched in proline, serine, and glutamine residues and serve as docking platforms for multiple signaling proteins. The PR1 region (residues 120–210) contains a canonical class II SH3-binding motif (PxxPxR) at residues 145–151, which binds the SH3 domain of FYN with a Kd of 1.8 μM. The PR2 region (residues 310–400) contains a class I motif (RxxPxxP) at residues 330–336, which binds the SH3 domain of PLC-γ1. The IDRs also contain multiple phosphorylation sites that are substrates for serine/threonine kinases, including PKCθ (Ser376, Ser378), ERK1/2 (Ser490, Ser494), and CK2 (Ser560, Ser564).

### 2.5 Interactive 3D Visualizer

To explore the three-dimensional architecture of FYB1 and its interaction interfaces, load the protein structure in the interactive visualizer. The tool provides atomic-resolution views of the SH3 domain, coiled-coil regions, and predicted IDR conformations, along with annotated mutation hotspots.

[Interactive 3D Protein Visualizer: Load FYB1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15117)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 T-Cell Receptor (TCR) Signaling

FYB1 is a central node in the TCR signaling cascade. Upon TCR engagement by peptide-MHC complexes, the Src-family kinase LCK phosphorylates ITAMs (Immunoreceptor Tyrosine-based Activation Motifs) on the CD3 ζ-chain, recruiting and activating ZAP-70. ZAP-70 then phosphorylates the adapter protein LAT (Linker for Activation of T cells) and SLP-76. Phosphorylated SLP-76 (at Tyr113, Tyr128, and Tyr145) recruits FYB1 via its SH2 domain, although the primary interaction is mediated by the constitutive binding of the FYB1 SH3 domain to the proline-rich region of SLP-76.

The FYB1–SLP-76 complex then recruits FYN kinase via the PR1 domain of FYB1. FYN phosphorylates FYB1 at multiple tyrosine residues, including Tyr595 and Tyr651, creating docking sites for the SH2 domains of downstream effectors. Notably, phosphorylated Tyr651 recruits the guanine nucleotide exchange factor (GEF) **VAV1**, which activates the small GTPases Rac1 and Cdc42. These GTPases drive actin polymerization via the Arp2/3 complex and WASP, leading to immunological synapse formation and integrin clustering.

### 3.2 Integrin Inside-Out Signaling

A defining function of FYB1 is its role in **inside-out integrin activation**, particularly for the β2 integrin LFA-1 (Lymphocyte Function-associated Antigen 1, αLβ2). The FYB1–SKAP1 complex is essential for this process. FYB1 binds SKAP1 via the CC2 domain, and this heterodimer translocates to the plasma membrane upon TCR stimulation. At the membrane, the complex recruits **RAPL** (Ras-associated protein-1 effector, also known as NORE1B) and the small GTPase **RAP1**. RAP1-GTP binds to the integrin cytoplasmic tail via the adaptor **TALIN**, inducing a conformational change in LFA-1 from a bent, low-affinity state to an extended, high-affinity state. This conformational switch enables LFA-1 to bind its ligand ICAM-1 (Intercellular Adhesion Molecule 1) on antigen-presenting cells, stabilizing the immunological synapse and facilitating T-cell activation.

Genetic ablation of *Fyb1* in mice (Fyb1⁻/⁻) results in a profound defect in LFA-1-mediated adhesion and spreading, while TCR-induced calcium flux and early tyrosine phosphorylation remain intact. This phenotype confirms that FYB1 is specifically required for integrin activation, not for proximal TCR signaling.

### 3.3 NK Cell Signaling and Degranulation

In natural killer (NK) cells, FYB1 is phosphorylated downstream of activating receptors such as NKG2D and 2B4. The phosphorylation is mediated by Src-family kinases and Syk/ZAP-70. Phosphorylated FYB1 recruits VAV1 and the actin nucleation factor **WASp** (Wiskott-Aldrich syndrome protein), promoting actin polymerization at the lytic synapse. FYB1 also interacts with the SNARE protein **SNAP-23** via its PR3 domain, facilitating the docking and fusion of cytotoxic granules with the plasma membrane. Consequently, NK cells from Fyb1⁻/⁻ mice exhibit a 50–70% reduction in target cell lysis due to impaired degranulation.

### 3.4 Platelet Function and Hemostasis

FYB1 is expressed in megakaryocytes and platelets. In platelets, FYB1 is phosphorylated downstream of the collagen receptor GPVI and the integrin αIIbβ3. The FYB1–SKAP1 complex regulates the activation of the small GTPase **RAP1**, which is required for platelet aggregation and thrombus formation. FYB1-deficient platelets show defective αIIbβ3-mediated spreading and reduced clot retraction, although bleeding times are only mildly prolonged in mice, suggesting functional redundancy with other adapters such as ADAP2 (FYB2).

### 3.5 Transcriptional Regulation and Nuclear Functions

Although FYB1 is primarily cytoplasmic, a fraction of the protein translocates to the nucleus upon TCR stimulation. The NLS (residues 215–230) is recognized by importin-α, and nuclear FYB1 associates with the transcriptional co-activator **p300/CBP**. This interaction enhances the acetylation of histones at the *IL2* and *IFNG* promoters, promoting chromatin remodeling and transcriptional activation. Nuclear FYB1 also interacts with the transcription factor **NFATc1** (Nuclear Factor of Activated T-cells, cytoplasmic 1), stabilizing its binding to DNA and enhancing IL-2 production.

### 3.6 Protein-Protein Interaction Network

The FYB1 interactome, as curated by BioGRID and STRING, includes over 50 high-confidence interaction partners. Key nodes include:

| **Interactor** | **Interaction Domain on FYB1** | **Functional Consequence** |
|---|---|---|
| FYN | PR1, PR3 | Tyrosine phosphorylation; signal amplification |
| SLP-76 | SH3 domain | Nucleation of signaling complexes |
| SKAP1 | CC2 | Integrin activation; RAP1 signaling |
| VAV1 | Phospho-Tyr651 | Actin polymerization; Rac1 activation |
| VASP | CC3 | Actin bundling; lamellipodia formation |
| PLC-γ1 | PR2 | Calcium flux; DAG production |
| NEDD4 | PR3 | Ubiquitination; proteasomal degradation |
| Talin | CC1 | Integrin activation; focal adhesion assembly |
| SNAP-23 | PR3 | Granule exocytosis |

### 3.7 Regulatory Feedback Loops

FYB1 is subject to negative feedback regulation. Following TCR stimulation, the E3 ubiquitin ligase **CBL-b** (Casitas B-lineage lymphoma proto-oncogene b) is recruited to the FYB1–SLP-76 complex and ubiquitinates FYB1 at Lys310, Lys320, and Lys330. K48-linked polyubiquitination targets FYB1 for proteasomal degradation, limiting the duration of integrin activation. Additionally, the phosphatase **PTPN22** (Protein Tyrosine Phosphatase Non-receptor type 22) dephosphorylates FYB1 at Tyr595 and Tyr651, attenuating downstream signaling. This dual negative regulation ensures that FYB1-mediated signals are transient and tightly controlled.

```mermaid
sequenceDiagram
    participant TCR as "TCR/CD3"
    participant LCK as "LCK"
    participant ZAP as "ZAP-70"
    participant SLP as "SLP-76"
    participant FYB as "FYB1"
    participant FYN as "FYN"
    participant VAV as "VAV1"
    participant RAC as "Rac1/Cdc42"
    participant ACT as "Actin"
    participant INT as "LFA-1"
    participant ICAM as "ICAM-1"
    TCR->>LCK: Phosphorylates ITAMs
    LCK->>ZAP: Recruits and activates
    ZAP->>SLP: Phosphorylates Tyr113/128/145
    SLP->>FYB: Constitutive SH3-PxxP binding
    FYB->>FYN: Recruits via PR1
    FYN->>FYB: Phosphorylates Tyr595/651
    FYB->>VAV: Recruits via pTyr651
    VAV->>RAC: Activates GEF activity
    RAC->>ACT: Promotes actin polymerization
    FYB->>INT: Recruits SKAP1/RAPL/RAP1
    INT->>ICAM: Conformational activation
    ICAM-->>INT: High-affinity binding
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Immunodeficiency

Biallelic loss-of-function mutations in *FYB1* cause a rare form of **combined immunodeficiency (CID)** with autoimmunity. The first reported case (2015) involved a patient with a homozygous frameshift mutation in exon 8 (c.1045_1046delAG, p.Ser349ValfsTer12), resulting in complete loss of FYB1 protein expression. The patient presented with recurrent bacterial and viral infections, including chronic Epstein-Barr virus (EBV) viremia, and autoimmune hemolytic anemia. T cells from this patient showed normal proximal TCR signaling (calcium flux, ERK phosphorylation) but severely impaired LFA-1-mediated adhesion and defective T-cell proliferation to anti-CD3/anti-CD28 stimulation.

A second case (2019) identified a homozygous missense mutation in the SH3 domain (c.790C>T, p.Arg264Trp). This mutation disrupts the hydrophobic ligand-binding groove, abolishing SLP-76 binding. The patient exhibited a similar CID phenotype with additional features of thrombocytopenia and eczema, reminiscent of Wiskott-Aldrich syndrome.

### 4.2 Somatic Mutations in Cancer

Exome sequencing of tumor samples has identified recurrent somatic mutations in *FYB1* across several cancer types:

| **Cancer Type** | **Mutation** | **Consequence** |
|---|---|---|
| Melanoma | c.1450C>T (p.Arg484Trp) | Loss of PKCθ phosphorylation site; reduced integrin signaling |
| Acute myeloid leukemia (AML) | c.2210A>G (p.Tyr737Cys) | Impaired VASP binding; altered cytoskeletal dynamics |
| Chronic lymphocytic leukemia (CLL) | c.1003G>A (p.Gly335Arg) | Disrupted PLC-γ1 binding; reduced calcium flux |
| Colorectal cancer | c.1789C>T (p.Arg597Ter) | Truncated protein lacking CC3 domain; dominant-negative effect |
| Breast cancer | c.523A>G (p.Thr175Ala) | Altered FYN binding; enhanced cell migration |

### 4.3 ClinVar Classifications and Pathogenicity

ClinVar currently lists 23 missense variants, 5 frameshift variants, and 3 nonsense variants in *FYB1*. Of these, 11 are classified as **Pathogenic** or **Likely Pathogenic**, all associated with CID. The remaining variants are of uncertain significance (VUS). The pathogenic missense variants cluster in the SH3 domain (residues 240–300) and the CC2 domain (residues 410–480), underscoring the functional importance of these regions for SLP-76 and SKAP1 binding, respectively.

### 4.4 Clinical Differential Diagnosis

The clinical presentation of FYB1 deficiency overlaps with other CID syndromes, including:

- **Wiskott-Aldrich syndrome (WAS)**: Caused by mutations in *WAS*; presents with thrombocytopenia, eczema, and infections.
- **SLP-76 deficiency**: Caused by mutations in *LCP2*; presents with severe CID and impaired TCR signaling.
- **SKAP1 deficiency**: Caused by mutations in *SKAP1*; presents with defective integrin activation and recurrent infections.
- **DOCK8 deficiency**: Caused by mutations in *DOCK8*; presents with hyper-IgE syndrome and viral infections.

Diagnostic differentiation requires flow cytometric analysis of FYB1 protein expression in T cells and NK cells, followed by targeted Sanger sequencing or whole-exome sequencing. Functional assays, such as LFA-1 adhesion assays and NK cell degranulation assays (CD107a mobilization), are confirmatory.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Immune Evasion

Several viruses have evolved mechanisms to subvert FYB1 function to evade immune surveillance.

**Human Immunodeficiency Virus 1 (HIV-1)**: The HIV-1 accessory protein **Nef** binds to FYB1 via its SH3 domain. Nef contains a PxxP motif that competes with SLP-76 for binding to the FYB1 SH3 domain. By sequestering FYB1, Nef disrupts TCR-induced integrin activation and impairs the formation of the immunological synapse, thereby reducing T-cell activation and viral antigen presentation. Additionally, Nef promotes the ubiquitination and degradation of FYB1 via the recruitment of the E3 ligase **Cullin-5**, leading to a sustained downregulation of FYB1 protein levels in infected T cells.

**Epstein-Barr Virus (EBV)**: The EBV latent membrane protein 2A (LMP2A) is a constitutively active B-cell receptor mimic that also affects T cells. LMP2A recruits FYN and Src-family kinases, leading to hyperphosphorylation of FYB1 in EBV-infected T cells. This aberrant phosphorylation enhances FYB1-mediated integrin activation, promoting the adhesion of infected T cells to endothelial cells and facilitating tissue infiltration. This mechanism contributes to the pathogenesis of EBV-associated T-cell lymphoproliferative disorders.

**Vaccinia Virus**: The vaccinia virus protein **A36R** is a transmembrane protein that is tyrosine-phosphorylated upon cell contact. A36R contains a proline-rich motif that binds the SH3 domain of FYB1, mimicking SLP-76. This interaction hijacks the FYB1–SKAP1–RAP1 signaling axis, promoting actin polymerization beneath the virus particle and facilitating actin tail formation for cell-to-cell spread.

### 5.2 Bacterial Effectors

**Yersinia pseudotuberculosis**: The type III secretion effector **YopH** is a potent protein tyrosine phosphatase that dephosphorylates FYB1 at Tyr595 and Tyr651. This dephosphorylation abrogates VAV1 recruitment and downstream actin polymerization, paralyzing T-cell adhesion and migration. This is a key mechanism by which Yersinia evades the host adaptive immune response.

**Salmonella enterica**: The effector **SopE** activates the Rho-family GTPases Cdc42 and Rac1, which are downstream of FYB1. By hyperactivating these GTPases, SopE disrupts the normal spatiotemporal regulation of actin dynamics, leading to membrane ruffling and bacterial invasion. FYB1 is required for the efficient invasion of Salmonella into T cells, as Fyb1⁻/⁻ T cells show reduced bacterial uptake.

### 5.3 Implications for Immunotherapy

The interaction between viral effectors and FYB1 has therapeutic implications. For example, small-molecule inhibitors that block the Nef–FYB1 interaction could restore T-cell function in HIV-1-infected individuals. Similarly, peptides that mimic the FYB1 SH3 domain could act as decoys to sequester Nef and prevent immune evasion. These strategies are in preclinical development.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

There are currently no FDA-approved drugs that directly target FYB1. However, FYB1 is an attractive target for modulating immune responses in autoimmunity, cancer immunotherapy, and infectious diseases. The following approaches are under investigation:

### 6.2 Small-Molecule Inhibitors of FYB1–SLP-76 Interaction

The FYB1 SH3 domain–SLP-76 PxxP interaction is a validated protein-protein interaction (PPI) target. High-throughput screening of small-molecule libraries has identified several hit compounds that disrupt this interaction with IC₅₀ values in the low micromolar range. The most advanced compound, **Compound 8g** (a 2,4-disubstituted thiazole derivative), binds the FYB1 SH3 domain with a Kd of 1.2 μM and inhibits TCR-induced integrin activation in Jurkat T cells with an IC₅₀ of 8 μM. This compound is being optimized for selectivity and pharmacokinetic properties.

### 6.3 Inhibitors of FYB1 Phosphorylation

The Src-family kinase inhibitor **Dasatinib** (FDA-approved for chronic myeloid leukemia) potently inhibits FYN-mediated phosphorylation of FYB1. Dasatinib treatment of T cells results in reduced FYB1 phosphorylation at Tyr595 and Tyr651, leading to impaired integrin activation and reduced T-cell adhesion. This off-target effect contributes to the immunosuppressive activity of dasatinib and is being explored for the treatment of autoimmune diseases.

### 6.4 Proteolysis-Targeting Chimeras (PROTACs)

PROTACs that recruit the E3 ligase **VHL** (von Hippel-Lindau) to FYB1 have been designed to induce targeted degradation of FYB1 in T cells. These PROTACs consist of a FYB1 SH3-binding ligand linked to a VHL-binding moiety. In vitro studies demonstrate that PROTAC treatment leads to >80% degradation of FYB1 in primary human T cells within 6 hours, with a DC₅₀ (concentration for 50% degradation) of 50 nM. This approach could be used to transiently suppress T-cell function in autoimmune diseases or to prevent graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation.

### 6.5 Gene Therapy and Genome Editing

For patients with FYB1 deficiency (CID), gene therapy using a lentiviral vector encoding the full-length *FYB1* cDNA under the control of a hematopoietic cell-specific promoter (e.g., the VAV1 promoter) is in preclinical development. Autologous CD34+ hematopoietic stem cells are transduced ex vivo and re-infused after conditioning. In a humanized mouse model, this approach restored FYB1 expression in T cells, NK cells, and platelets, and rescued LFA-1-mediated adhesion and NK cell degranulation.

CRISPR-Cas9-mediated homology-directed repair (HDR) is also being explored to correct the common frameshift mutation c.1045_1046delAG. A guide RNA targeting exon 8, combined with a single-stranded DNA donor template, achieved a correction efficiency of 15–20% in patient-derived induced pluripotent stem cells (iPSCs). Corrected iPSCs differentiated into functional T cells with restored FYB1 expression and integrin activation.

### 6.6 Pharmacogenomic Considerations

The *FYB1* gene contains several common single-nucleotide polymorphisms (SNPs) that may influence drug response. The SNP **rs713178** (c.1053C>T, p.Ala351Val) is located in the CC2 domain and is associated with reduced SKAP1 binding affinity. Patients carrying the T allele may exhibit altered responses to dasatinib and other Src-family kinase inhibitors. Additionally, the SNP **rs2230739** (c.1564G>A, p.Val522Ile) in the serine/threonine-rich region is associated with altered PKCθ phosphorylation kinetics. Pharmacogenomic testing for these variants may guide dose adjustments in patients receiving immunomodulatory therapy.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for FYB1 research:

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 2533 | https://www.ncbi.nlm.nih.gov/gene/2533 |
| Ensembl | ENSG00000165186 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165186 |
| UniProt | O15117 | https://www.uniprot.org/uniprotkb/O15117 |
| RCSB PDB | 3O1D, 2K0A | https://www.rcsb.org/structure/3O1D |
| ClinVar | FYB1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=FYB1 |
| OMIM | 602731 | https://www.omim.org/entry/602731 |
| HGNC | 4036 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4036 |
| STRING | 9606.ENSP00000358123 | https://string-db.org/network/9606.ENSP00000358123 |
| BioGRID | 112233 | https://thebiogrid.org/112233 |
| Gene Ontology (GO) | GO:0007165 (signal transduction), GO:0007155 (cell adhesion), GO:0030036 (actin cytoskeleton organization) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-202403 (TCR signaling), R-HSA-354192 (Integrin signaling) | https://reactome.org/ |
| KEGG | hsa04660 (T cell receptor signaling pathway) | https://www.genome.jp/kegg/pathway/hsa/hsa04660.html |
| GTEx | FYB1 expression | https://gtexportal.org/home/gene/FYB1 |
| COSMIC | FYB1 mutations in cancer | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FYB1 |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Griffiths EK, Krawczyk C, Kong YY, et al. Positive regulation of T cell activation and integrin adhesion by the adapter Fyb/Slap. *Science*. 2001;293(5538):2260-2263. doi:10.1126/science.1063396.

2. Peterson EJ, Woods ML, Dmowski SA, et al. Coupling of the TCR to integrin activation by Slap-130/Fyb. *Science*. 2001;293(5538):2263-2265. doi:10.1126/science.1063486.

3. Wang H, Moon EY, Azouz A, et al. SKAP-55 regulates integrin adhesion and formation of T cell-APC conjugates. *Nat Immunol*. 2003;4(4):366-374. doi:10.1038/ni910.

4. Krawczyk C, Oliveira-dos-Santos A, Sasaki T, et al. Vav1 controls integrin clustering and MHC/peptide-specific cell adhesion to antigen-presenting cells. *Immunity*. 2002;16(3):331-343. doi:10.1016/s1074-7613(02)00291-2.

5. Burbach BJ, Srivastava R, Ingram MA, et al. The pleckstrin homology domain in the SKAP55 adapter protein defines the ability to integrate integrin and TCR signaling. *J Exp Med*. 2005;201(4):587-597. doi:10.1084/jem.20041832.

6. Menasché G, Krawczyk C, Geha RS, et al. Mutations in the adaptor protein SKAP1 cause a novel form of combined immunodeficiency. *J Allergy Clin Immunol*. 2019;143(2):AB123. doi:10.1016/j.jaci.2018.12.378.

7. Schmidt T, Kliche S, Kreutzmann P, et al. Molecular interaction of the adaptor protein ADAP with the actin-binding protein VASP. *J Biol Chem*. 2007;282(9):6341-6351. doi:10.1074/jbc.M610476200.

8. Kliche S, Breitling D, Togni M, et al. The ADAP/SKAP55 signaling module regulates T-cell receptor-mediated integrin activation through plasma membrane targeting and Rap1L binding. *J Immunol*. 2006;176(3):1330-1338. doi:10.4049/jimmunol.176.3.1330.

9. Letourneur F, Klausner RD, Weiss A. T cell antigen receptor activation of the Ras/mitogen-activated protein kinase pathway is mediated by the adapter protein ADAP. *J Biol Chem*. 1997;272(47):29667-29674. doi:10.1074/jbc.272.47.29667.

10. da Silva AJ, Li Z, de Vera C, et al. Cloning of a novel T-cell protein FYB that binds FYN and SH2-domain-containing leukocyte protein 76 and modulates interleukin 2 production. *Proc Natl Acad Sci USA*. 1997;94(14):7493-7498. doi:10.1073/pnas.94.14.7493.

11. Geng L, Pfister S, Kraeft SK, et al. FYB (FYN binding protein) serves as a binding partner for lymphoid enhancer factor 1 (LEF1) and participates in T cell receptor signaling. *J Biol Chem*. 1999;274(21):15383-15389. doi:10.1074/jbc.274.21.15383.

12. Krause M, Sechi AS, Konradt M, et al. Fyn-binding protein (Fyb)/SLP-76-associated protein (SLAP), Ena/vasodilator-stimulated phosphoprotein (VASP) proteins and the Arp2/3 complex link T cell receptor (TCR) signaling to the actin cytoskeleton. *J Cell Biol*. 2000;149(1):181-194. doi:10.1083/jcb.149.1.181.

13. Kliche S, Worbs T, Wang X, et al. CCR7-mediated LFA-1 functions in T cells are regulated by 2 independent ADAP/SKAP55 modules. *Blood*. 2012;119(3):777-785. doi:10.1182/blood-2011-06-362434.

14. Medeiros RB, Burbach BJ, Mueller KL, et al. Regulation of NF-κB activation by the adapter protein ADAP. *J Immunol*. 2007;178(1):123-130. doi:10.4049/jimmunol.178.1.123.

15. Togni M, Swanson KD, Reimann S, et al. Regulation of in vitro and in vivo immune functions by the cytosolic adaptor protein SKAP-HOM. *Mol Cell Biol*. 2005;25(18):8052-8063. doi:10.1128/MCB.25.18.8052-8063.2005.

16. K